- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00662324
Development of a Clinical Trial Specific Question Prompt List
The purpose of this study is to develop a Question Prompt List (QPL) about clinical trials for cancer patients and find out what cancer patients and their caregivers think of the QPL. A QPL is a list of questions patients might want to ask their doctors during their appointments.
We will conduct three focus groups to talk about using QPL's as a new way to recruit patients like you to clinical trials. The three groups will be made of patients who have and have not participated in clinical trials, their caregivers and doctors. This study is also being done to learn about how the QPL affects the question asking behavior of patients during their appointments with doctors at Memorial SloanKettering Cancer Center (MSKCC).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
New York
-
New York, New York, États-Unis, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Population Segment 1 who have participated in a clinical trial
- Diagnosis and treatment at MSKCC of lung, prostate or breast cancer
- Completion of a Phase I, II, or III clinical trial at MSKCC
- Ability to provide informed consent
Patient caregiver eligibility requirements will be:
- Nomination by patient as the primary caregiver
- Ability to provide informed consent
Population Segment 2 who have not participated in a clinical trial:
- Diagnosis and treatment at MSKCC of lung, prostate or breast cancer or the primary patient caregiver
- Ability to provide informed consent
Patient caregiver eligibility requirements will be:
- Nomination by patient as the primary caregiver
- Ability to provide informed consent
Population Segment 3 who are health care professionals:
- A current health care professional at MSKCC
- Current involvement in recruiting patients with lung, prostate or breast cancer to Phase I,II, or III clinical trials at MSKCC
- Ability to provide informed consent
Exclusion Criteria:
Potential subjects will be considered ineligible for either/both phases of this study if they are:
- Fewer than 18 years of age
- Cognitively or physically impaired, rendering them incapable of providing informed consent to participate in the study
- Population Segment 2 participants will be excluded if they have ever participated in a clinical trial.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
1
Trial experienced cancer patients and their primary caregivers.
|
Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded. During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial. The focus group to last from 60 to 90 minutes. Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded. During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future. We expect the focus group to last from 60 to 90 minutes. MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded. During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials. Expect the focus group to last from 60 to 90 minutes. |
2
Trial naive cancer patients and their caregivers.
|
Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded. During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial. The focus group to last from 60 to 90 minutes. Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded. During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future. We expect the focus group to last from 60 to 90 minutes. MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded. During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials. Expect the focus group to last from 60 to 90 minutes. |
3
Health care professionals who are involved in running Phase I, II or III clinical trials.
|
Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded. During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial. The focus group to last from 60 to 90 minutes. Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded. During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future. We expect the focus group to last from 60 to 90 minutes. MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded. During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials. Expect the focus group to last from 60 to 90 minutes. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
To develop a targeted Question Prompt List for Clinical Trials and evaluate its acceptability to cancer patients considering clinical trial participation.
Délai: conclusion of study
|
conclusion of study
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
To explore the utility of the Question Prompt List for Clinical Trials in oncology consultations containing a discussion of a Phase I, II or III clinical trial.
Délai: conclusion of study
|
conclusion of study
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Carmen Bylund, PhD, Memorial Sloan Kettering Cancer Center
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 08-042
- NIH/NCI R03 CA130598-01
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer du sein
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie
Essais cliniques sur focus groups
-
University of LisbonAssociacao Protectora dos Diabeticos de PortugalComplété
-
University Hospital, BrestPas encore de recrutement
-
Children's National Research InstituteComplétéFormation sur la sécurité des sièges d'auto pour enfantsÉtats-Unis
-
Aarhus University HospitalUniversity of AarhusComplétéCancer du sein féminin | Peur de la récidive du cancerDanemark
-
Arizona Oncology ServicesInconnueCancer du sein localisé | Cancer localisé de la prostate | Patients recevant une radiothérapie externeÉtats-Unis
-
hearX GroupUniversity of PretoriaComplété
-
Montefiore Medical CenterThe FAR FundComplétéParentalité | Relation parent-enfantÉtats-Unis
-
Boston Children's HospitalComplétéStress, Psychologique | Problème d'acculturationÉtats-Unis
-
University of South FloridaNational Cancer Institute (NCI)Recrutement
-
Amsterdam UMC, location VUmcRed Cross Hospital BeverwijkComplétéCicatrice hypertrophique | ChéloïdePays-Bas